search
Back to results

Molehill Mountain Feasibility Study.

Primary Purpose

Anxiety, Autism

Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Molehill Mountain app
Molehill Mountain app
Sponsored by
King's College London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Anxiety

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 16-years.
  • Autism diagnosis.
  • Current mild-to-severe anxiety symptom severity, as assessed at screening (and currently in touch with mental health services e.g., referred, on the waitlist).
  • Able and willing to provide verbal and written informed consent to take part in the study.
  • Access to Molehill Mountain app via SmartPhone or other Smart device.

Exclusion Criteria:

  • Difficulties with reading/ writing to the extent that the app is inaccessible.
  • High risk of self-harm that make participation in the study inappropriate for the individual's current level of clinical need (as assessed by clinical team).
  • Attended ≥ 6 sessions of individual or group therapy (e.g., cognitive behavioural therapy) in the past 6-months, which would make it impossible to parse out the effects of the app from existing therapy.
  • If using psychotropic medication, this medication/ dose must have been stable for a minimum of 8-weeks on entry to the study.

Sites / Locations

  • King's College LondonRecruiting
  • South London and Maudsley NHS Foundation Trust (SLaM)Recruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Feasibility/ acceptability

Arm Description

Outcomes

Primary Outcome Measures

Change in 7-item Generalised Anxiety Disorder Scale (GAD-7)
Minimum score = 0; Maximum score = 21; Higher scores indicate more severe anxiety.
App acceptability/ feasibility survey
A survey developed by the investigator team to assess the acceptability and feasibility of Molehill Mountain app use by autistic adolescents/ adults in a clinically derived sample. Key indices incorporated in post-study app use experience surveys include: 1) the preparedness of participants to be randomised in a future trial; 2) ease of app administration and use; 3) preferred app features, content, and structure; 4) non-preferred app features, content, and structure; 5) experiences of app technical functionality; and 6) subjective reflections on the impact of app use on anxiety and everyday wellbeing/ functioning.

Secondary Outcome Measures

Change in Medication/ service use
To indicate changes in medication (number of medications, dose, frequency) and/ or clinical service use (number of appointments, attendance, length of engagement with services) with using the Molehill Mountain app to manage anxiety.
Change in Goal Attainment Scaling
Participants will choose 3 priority goals from a list of functional outcomes, including feeling less anxious, understanding anxiety better, understanding anxiety triggers better, and reducing anxiety across key areas of everyday life (e.g., relationships, social encounters, communication, school/ work, leisure, sensory). Participants will rate their progress in relation to these 3 goals on a scale from 1 (a very long way from this goal) to 7 (achieved this goal).

Full Information

First Posted
February 4, 2022
Last Updated
October 10, 2023
Sponsor
King's College London
Collaborators
South London and Maudsley NHS Foundation Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT05302167
Brief Title
Molehill Mountain Feasibility Study.
Official Title
Feasibility Study of an Adapted App-based Anxiety Intervention ('Molehill Mountain') for Autistic People.
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 6, 2022 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
King's College London
Collaborators
South London and Maudsley NHS Foundation Trust

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Up to half of autistic people experience anxiety symptoms, which can have a significant impact on everyday wellbeing. However, there are currently very few effective, evidence-based interventions to support autistic people in managing anxiety; and many autistic people face barriers in accessing inperson health and social care services. Therefore, developing new interventions (and/ or adapting existing ones) that improve anxiety, in a way that meets the needs of autistic people, represents the autism community's number one priority for research and clinical practice. Addressing this priority, the investigators will test the acceptability and feasibility of a new, app-based therapeutic approach for anxiety ('Molehill Mountain') that has been developed with, and adapted for, autistic people aged 12-years and over using adapted Cognitive Behavioural therapy principles. This means that information will be collected from autistic people accessing clinical services on whether they would choose to use the anxiety app, whether the app is simple to administer and use, how it is used, how it can be improved, and whether it is effective in reducing anxiety symptoms and/ or enhancing other outcomes, such as everyday wellbeing and functioning. The evidence from this project will inform the future optimisation and implementation of Molehill Mountain in a randomised-controlled trial, with the ultimate aim of transforming long-term healthcare delivery for autistic people.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anxiety, Autism

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Feasibility/ acceptability
Arm Type
Experimental
Intervention Type
Behavioral
Intervention Name(s)
Molehill Mountain app
Intervention Description
The Molehill Mountain app (currently Version 2) was developed jointly by King's College London (Lead: Prof Emily Simonoff; Advisors: Dr Ann Ozsivadjian and Dr Rachel Kent) and UK autism charity Autistica (Product Owner: Andy Clarke; Product Designer: Joanna Alpe) for use by autistic people aged ≥12-years (https://www.autistica.org.uk/molehill-mountain). The app was designed based on a self-guided paper-and-pencil CBT toolkit adapted for autism by Professor Emily Simonoff. Since the first version of Molehill Mountain (a two-week long programme) was launched in 2016, and based on surveys of autistic people and five rounds of prototype testing, the Molehill Mountain V2 app was relaunched in April 2021 as a three-month long app-based programme with enhanced interactive features. This 3-month V2 Molehill Mountain app, with enhanced interactive features supporting short daily logins, that will be implemented in the current study.
Intervention Type
Device
Intervention Name(s)
Molehill Mountain app
Intervention Description
As above.
Primary Outcome Measure Information:
Title
Change in 7-item Generalised Anxiety Disorder Scale (GAD-7)
Description
Minimum score = 0; Maximum score = 21; Higher scores indicate more severe anxiety.
Time Frame
Week 0 (+/-2); Week 13 (+/-2); Week 24 (+/- 4); Week 32 (+/-4); Week 41 (+/-4)
Title
App acceptability/ feasibility survey
Description
A survey developed by the investigator team to assess the acceptability and feasibility of Molehill Mountain app use by autistic adolescents/ adults in a clinically derived sample. Key indices incorporated in post-study app use experience surveys include: 1) the preparedness of participants to be randomised in a future trial; 2) ease of app administration and use; 3) preferred app features, content, and structure; 4) non-preferred app features, content, and structure; 5) experiences of app technical functionality; and 6) subjective reflections on the impact of app use on anxiety and everyday wellbeing/ functioning.
Time Frame
Week 13 (+/-2)
Secondary Outcome Measure Information:
Title
Change in Medication/ service use
Description
To indicate changes in medication (number of medications, dose, frequency) and/ or clinical service use (number of appointments, attendance, length of engagement with services) with using the Molehill Mountain app to manage anxiety.
Time Frame
Week 0 (+/-2); Week 13 (+/-2); Week 24 (+/- 4); Week 32 (+/-4); Week 41 (+/-4)
Title
Change in Goal Attainment Scaling
Description
Participants will choose 3 priority goals from a list of functional outcomes, including feeling less anxious, understanding anxiety better, understanding anxiety triggers better, and reducing anxiety across key areas of everyday life (e.g., relationships, social encounters, communication, school/ work, leisure, sensory). Participants will rate their progress in relation to these 3 goals on a scale from 1 (a very long way from this goal) to 7 (achieved this goal).
Time Frame
Week 0 (+/-2); Week 13 (+/-2); Week 24 (+/- 4); Week 32 (+/-4); Week 41 (+/-4)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 16-years. Autism diagnosis. Current mild-to-severe anxiety symptom severity, as assessed at screening (and currently in touch with mental health services e.g., referred, on the waitlist). Able and willing to provide verbal and written informed consent to take part in the study. Access to Molehill Mountain app via SmartPhone or other Smart device. Exclusion Criteria: Difficulties with reading/ writing to the extent that the app is inaccessible. High risk of self-harm that make participation in the study inappropriate for the individual's current level of clinical need (as assessed by clinical team). Attended ≥ 6 sessions of individual or group therapy (e.g., cognitive behavioural therapy) in the past 6-months, which would make it impossible to parse out the effects of the app from existing therapy. If using psychotropic medication, this medication/ dose must have been stable for a minimum of 8-weeks on entry to the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bethany Oakley, PhD
Phone
+44 (0) 207 848 0820
Email
bethany.oakley@kcl.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Emily Simonoff, MD; PhD
Organizational Affiliation
King's College London
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Declan Murphy, MD; PhD
Organizational Affiliation
MD; PhD
Official's Role
Principal Investigator
Facility Information:
Facility Name
King's College London
City
London
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr Bethany Oakley, PhD
Facility Name
South London and Maudsley NHS Foundation Trust (SLaM)
City
London
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Prof Emily Simonoff, MD, PhD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The research team will produce a fully anonymised (i.e., no longer coded, or including any identifiable or special category data) quantitative dataset at the end of the study that will be openly accessible. Participant consent will be gained to do so.
IPD Sharing Time Frame
The dataset will become available at the end of the study (estimated March 2023). Due to its fully anonymised nature, this dataset will be available indefinitely.

Learn more about this trial

Molehill Mountain Feasibility Study.

We'll reach out to this number within 24 hrs